Circulating tumour cells in patients with urothelial tumours: Nrichment and in vitro culture

Canadian Urological Association Journal

Volumn 8, Issue 9-10, 2014, Pages e715-e720

  Kolostova, Katarina ^a   Cegan, Martin ^b   Bobek, Vladimir ^a,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Masaryk s Hospital in Usti nad Labem   (Czech Republic)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919913107     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.1978     Document Type: Article

References (22)

1. Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: Systematic review and meta-analysis. BMC Cancer 2011;4:336. http://dx.doi.org/10.1186/1471-2407-11-336
2. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9. http://dx.doi.org/10.1158/1078-0432.CCR-08-0872
3. Rink M, Chun FK, Minner S, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 2011;107:1668-75. http://dx.doi.org/10.1111/j.1464-410X.2010.09562.x
4. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-5.
5. Fidler IJ. Metastasis: Guantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J. Natl. Cancer Inst 1970;45:773-82.
6. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976;36:889-94.
7. Friedlander TW, Fong L The end of the beginning: Circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol 2014;32:1104-6. http://dx.doi.org/10.1200/JCO.2013.54.7307. Epub 2014 Mar 10.
8. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011;17:3903-12. http://dx.doi.org/10.1158/1078-0432.CCR-10-2650
9. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9.
10. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castrationresistant prostate cancer. Clin Cancer Res 2007;13:7053-8.
11. Goodman OB Jr, Symanowski JT, Loudyi A, et al. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer 2011;9:31-8.
12. Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in Southwest Oncology Group trial S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32:1136-42. http://dx.doi.org/10.1200/JCO.2013.51.7417
13. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castrationresistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-9. http://dx.doi.org/10.1016/S1470-2045(08)70340-1
14. Xu T, Lu B, Tai YC, et al. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res 2010;70:6420-6.
15. Lin HK, Zheng S, Wiliams AJ, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010;16:1-8.
16. Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castrationresistantprostate cancer patients treated with abiraterone acetate. Eur Urol 2011;60:897-904.
17. Jiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010;56:1492-5. http://dx.doi.org/10.1373/clinchem.2010.143297
18. Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011;29:293s.
19. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
20. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
21. Pantel K, Deńeve E, Nocca D, et al. Circulating epitelial cells in patients with benign colon diseases. Clin Chem 2012;58:936-40.
22. Mikolajczyk L, Millar S, Tsinberg P, et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011;252361. http://dx.doi.org/10.1155/2011/252361. Epub 2011 Apr 19.